HPV-YAP1 Oncogenic Alliance Drives Malignant Transformation of Fallopian Tube Epithelial Cells

Overview

Journal EMBO Rep

Specialty Molecular Biology

Date 2024 Sep 13

PMID 39271776

Authors

Chunbo He

Xiangmin Lv

Jiyuan Liu

Jinpeng Ruan

Peichao Chen

Cong Huang

Peter C Angeletti

Guohua Hua

Madelyn Leigh Moness

Davie Shi

Anjali Dhar

Siyi Yang

Savannah Murphy

Isabelle Montoute

Xingcheng Chen

Kazi Nazrul Islam

Sophia George

Tan A Ince

Ronny Drapkin

Chittibabu Guda

John S Davis

Cheng Wang

Affiliations

Soon will be listed here.

Abstract

High grade serous ovarian carcinoma (HGSOC) is the most common and aggressive ovarian malignancy. Accumulating evidence indicates that HGSOC may originate from human fallopian tube epithelial cells (FTECs), although the exact pathogen(s) and/or molecular mechanism underlying the malignant transformation of FTECs is unclear. Here we show that human papillomavirus (HPV), which could reach FTECs via retrograde menstruation or sperm-carrying, interacts with the yes-associated protein 1 (YAP1) to drive the malignant transformation of FTECs. HPV prevents FTECs from natural replicative and YAP1-induced senescence, thereby promoting YAP1-induced malignant transformation of FTECs. HPV also stimulates proliferation and drives metastasis of YAP1-transformed FTECs. YAP1, in turn, stimulates the expression of the putative HPV receptors and suppresses the innate immune system to facilitate HPV acquisition. These findings provide critical clues for developing new strategies to prevent and treat HGSOC.

References

Baseman J, Koutsky L . The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32 Suppl 1:S16-24. DOI: 10.1016/j.jcv.2004.12.008. View

Bhat P, Mattarollo S, Gosmann C, Frazer I, Leggatt G . Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011; 239(1):85-98. DOI: 10.1111/j.1600-065X.2010.00966.x. View

Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

Buck C, Thompson C, Roberts J, Muller M, Lowy D, Schiller J . Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006; 2(7):e69. PMC: 1500806. DOI: 10.1371/journal.ppat.0020069. View

Cardone G, Moyer A, Cheng N, Thompson C, Dvoretzky I, Lowy D . Maturation of the human papillomavirus 16 capsid. mBio. 2014; 5(4):e01104-14. PMC: 4128349. DOI: 10.1128/mBio.01104-14. View

Chan P, Seraj I, Kalugdan T, King A . Evidence for ease of transmission of human papillomavirus DNA from sperm to cells of the uterus and embryo. J Assist Reprod Genet. 1996; 13(6):516-9. DOI: 10.1007/BF02066536. View

Crum C, McKeon F, Xian W . The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol. 2012; 55(1):24-35. PMC: 3319355. DOI: 10.1097/GRF.0b013e31824b1725. View

CULLEN A, Reid R, Campion M, Lorincz A . Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991; 65(2):606-12. PMC: 239798. DOI: 10.1128/JVI.65.2.606-612.1991. View

Daud I, Scott M, Ma Y, Shiboski S, Farhat S, Moscicki A . Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer. 2010; 128(4):879-86. PMC: 2952342. DOI: 10.1002/ijc.25400. View

10.

Day P, Lowy D, Schiller J . Papillomaviruses infect cells via a clathrin-dependent pathway. Virology. 2003; 307(1):1-11. DOI: 10.1016/s0042-6822(02)00143-5. View

11.

Di Paolo N . Recognition of human oncogenic viruses by host pattern-recognition receptors. Front Immunol. 2014; 5:353. PMC: 4105630. DOI: 10.3389/fimmu.2014.00353. View

12.

DiMauro T, David G . Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets. 2010; 10(8):869-76. PMC: 4023163. DOI: 10.2174/156800910793357998. View

13.

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View

14.

Doorbar J . The papillomavirus life cycle. J Clin Virol. 2005; 32 Suppl 1:S7-15. DOI: 10.1016/j.jcv.2004.12.006. View

15.

Duus A, Zheng G, Baandrup L, Faber M, Kjaer S . Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure. Gynecol Oncol. 2023; 177:125-131. DOI: 10.1016/j.ygyno.2023.08.016. View

16.

Edwards T, Helmus M, Koeller K, Bashkin J, Fisher C . Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. J Virol. 2013; 87(7):3979-89. PMC: 3624211. DOI: 10.1128/JVI.03473-12. View

17.

Erickson B, Conner M, Landen Jr C . The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013; 209(5):409-14. PMC: 3937451. DOI: 10.1016/j.ajog.2013.04.019. View

18.

Fisher C . Recent Insights into the Control of Human Papillomavirus (HPV) Genome Stability, Loss, and Degradation. J Clin Med. 2015; 4(2):204-30. PMC: 4366058. DOI: 10.3390/jcm4020204. View

19.

Frazer I . Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2008; 384(2):410-4. DOI: 10.1016/j.virol.2008.10.004. View

20.

Haws A, He Q, Rady P, Zhang L, Grady J, Hughes T . Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods. 2004; 122(1):87-93. DOI: 10.1016/j.jviromet.2004.08.007. View